✦ LIBER ✦

PCA6: COST-EFFECTIVENESS OF GEMCITABINE AS FIRST-LINE THERAPY FOR PATIENTS WITH ADVANCED PANCREATIC CANCER

✍ Scribed by S Trippoli; A Messori

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase I study of imexon plus gemcitabi

✍ Steven J. Cohen; Mark M. Zalupski; Manuel R. Modiano; Paul Conkling; Yehuda Z. P 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 275 KB

Cost-effectiveness of anastrozole versus

✍ W.Robert Simons; David Jones; Aman Buzdar 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 175 KB

CH1: COST-EFFECTIVENESS ANALYSIS OF IRIN

✍ C Schmitt; C Levy-Piedbois; M Frappe; I Durand-Zaleski 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 54 KB

PCN5: FIRST-LINE THERAPY FOR ADVANCED BR

✍ M Marchetti; N Liberato; G Barosi 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 52 KB

Bevacizumab plus gemcitabine and oxalipl

✍ David Fogelman; Mehrdad Jafari; Gauri R. Varadhachary; Henry Xiong; Susie Bulloc 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 216 KB

Phase II trial of weekly docetaxel and g

✍ Sujith Kalmadi; Giles McNeill; Mellar Davis; David Peereboom; David Adelstein; T 📂 Article 📅 2006 🏛 Springer US 🌐 English ⚖ 68 KB